Today: 20 May 2026
Browse Category

NASDAQ:GMAB 30 December 2025 - 8 May 2026

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie shares fell 1.1% to $214.35 Friday after partner Genmab said their blood cancer drug epcoritamab failed to meet the main survival goal in a Phase 3 trial. Genmab’s U.S. shares dropped over 7%. AbbVie reported a benefit for progression-free survival but not overall survival. Investors await AbbVie’s earnings report on Feb. 4.
18 January 2026
····
Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

Genmab A/S shares fell 3.3% to $30.44 in New York after the company dropped further development of acasunlimab, a late-stage cancer drug, following a portfolio review. Genmab said the move does not affect its 2025 guidance and will focus on other pipeline drugs. The company also completed its acquisition of Merus N.V., paying $97 per share in a tender offer. Merus requested Nasdaq delist its stock after the merger.
31 December 2025
···
Merus stock halted today as Genmab buyout closes: what happens to MRUS shares and the $97 cash payout

Merus stock halted today as Genmab buyout closes: what happens to MRUS shares and the $97 cash payout

Merus N.V. shares were halted Tuesday after Nasdaq confirmed Genmab’s $97-a-share cash acquisition closed, with trading set for suspension Dec. 31. Holders will receive $97 per share minus a $10.67 Dutch dividend withholding tax, leaving about $86.33 before any refund. Merus requested delisting, and two directors resigned as the merger became effective. Genmab’s U.S. shares fell about 2% in late-morning trading.
30 December 2025
··

Stock Market Today

  • Sensex and Nifty Poised for Lower Open Amid Crude Rise and Geopolitical Tensions
    May 20, 2026, 1:21 AM EDT. Indian stock markets are expected to open lower on the back of rising crude oil prices, higher U.S. Treasury yields, and escalating tensions involving Iran. These factors are dampening investor sentiment. Additionally, persistent foreign portfolio selling, elevated market volatility, and critical technical support levels are causing traders to remain cautious ahead of the session.

Latest articles

Wall Street Hit by Yield Jolt With Nvidia Up Next

Wall Street Hit by Yield Jolt With Nvidia Up Next

20 May 2026
U.S. stock ETFs remained lower late Tuesday after Wall Street’s main indexes fell for a third straight session, pressured by rising Treasury yields and caution ahead of Nvidia’s earnings. The SPDR S&P 500 ETF dropped 0.7% to $733.73. The 10-year Treasury yield hit 4.687%, its highest since January 2025, before easing. Nvidia shares slipped 0.7% after hours, with traders bracing for a major move post-earnings.
Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

20 May 2026
Viavi Solutions shares dropped 7.1% in after-hours trading Tuesday after the company announced a $500 million public stock offering aimed at repaying debt. The offering, unveiled just after the Nasdaq close, could add roughly 10.1 million new shares. Viavi plans to use proceeds to pay down a $450 million loan. Total debt would fall to $650 million, according to a preliminary SEC filing.
Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

20 May 2026
Analog Devices agreed to acquire Empower Semiconductor for $1.5 billion in cash, sending ADI shares up 1.36% to $419.95 in after-hours trading after closing down 1.02%. The deal, approved by both boards, is expected to close in the second half of 2026 pending regulatory review. Empower CEO Tim Phillips will continue to lead integrated voltage regulator work after the merger.
Go toTop